Prescription change from cinacalcet hydrochloride to evocalcet in hemodialysis patients with secondary hyperparathyroidism - Switching from cinacalcet hydrochloride to evocalcet in hemodialysis patients with SHPT

PTH increased for several months, while Ca transiently increased. The cinacalcet dose just before the switch was positively correlated with change in the amplitudes of PTH and Ca. The change in the amplitude of PTH was positively correlated with the change in the amplitude of Ca, suggesting that the transient Ca elevation was derived from the bone. Some patients stopped taking drugs that stimulate GI motility. The proportion of patients with GI symptoms decreased and medication adherence increased.